Preclinical findings demonstrated enhanced apoptosis, G1-phase cell cycle arrest, and reduced colony-forming capacity in JAK2-mutant HEL cells and primary bone marrow mononuclear cells (BMMNCs) from MPN patients. This evidence concerns the gene JAK2 and myeloproliferative disorder.